In a US clinical trial
The majority of IBS-D patients had an abnormal composition of bacteria in the gut1,*
*Data from 93 patients with IBS-D in a prospective TARGET 3 substudy utilizing lactulose breath testing to predict response to XIFAXAN.1
What is gut dysbiosis?
Alterations in specific bacterial groups and microbial community diversity are known as gut dysbiosis. It is an imbalance in the ratio of harmful and helpful bacterial groups.2
Studies show that many patients with IBS-D have a bacterial imbalance in the gut3-5
Bacterial imbalance has been linked to symptoms of IBS-D3,6,7
As the body of evidence continues to grow in support of the link between gut dysbiosis and IBS-D, so too does the need for compatible pharmacologic therapies.